Loading company
TELA Bio, Inc.
TELA · Nasdaq · ·
$1.23-0.8%Sep 29 close
- 1M
- +75.7%
- 6M
- +117.7%
- 1Y
- -17.4%
- 5Y
- -90.8%
What TELA Bio, Inc. reported on August 10, 2026
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $19.3M | $20.2M | -4.49% |
| Profit | -$11.3M | -$9.9M | -13.49% |
| Profit per share | -$0.20 | -$0.22 | +9.09% |
| Free Cash Flow | -$9.4M | -$8M | -17.72% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Earnings calls
TELA Bio, Inc. has no earnings call transcript available.
What management said
“I am honored to join TELA Bio at such an exciting time in the Company's evolution. One reason I joined TELA is the superiority of our differentiated product portfolio. OviTex long-term data has continuously shown recurrence rates in the low single-digits, whereas other hernia repair materials have recurrence rates consistently 10 times higher than that. “Unfortunately, the financial performance of the business does not reflect the superiority of the portfolio. Our second quarter revenue was negatively impacted by a decline in OviTex PRS volumes and continued price and mix headwinds in hernia procedures. In response, we have returned to a sales structure designed to reinforce cross-selling among our field teams, and with a clear focus on returning to growth in the second half the year,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
How the share price reacted
Releases land after the close or before the open, so the move is the session that follows.
Close before
$0.93
Aug 10, 2026
Close after
$0.79
Aug 11, 2026
Move
-15.05%
219.7K shares traded, against a normal 88.79K
What TELA Bio, Inc. does
TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy. The Company is committed to providing surgeons with advanced, economically effective soft-tissue reconstruction solutions that leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from TELA Bio, Inc.’s Item 2.02 8-K filed August 10, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.